E Fund Management’s Agios Pharmaceuticals AGIO Stock Holding History

E Fund Management’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$291K	Sell	7,837 -5,078	-39%	-$154K	0.01%	387
2026 Q1	$437K	Buy	+12,915	New	+$366K	0.01%	312
2025 Q2	–	Sell	-8,750	Closed	-$256K	–	396
2025 Q1	$256K	Buy	+8,750	New	+$290K	0.01%	338
2024 Q4	–	Sell	-5,751	Closed	-$256K	–	396
2024 Q3	$256K	Buy	5,751 +1,083	+23%	+$49.2K	0.01%	281
2024 Q2	$201K	Sell	4,668 -5,785	-55%	-$209K	0.01%	292
2024 Q1	$306K	Buy	+10,453	New	+$280K	0.02%	273
2023 Q3	–	Sell	-8,793	Closed	-$249K	–	293
2023 Q2	$249K	Sell	8,793 -2,908	-25%	-$72.4K	0.02%	243
2023 Q1	$269K	Buy	11,701 +605	+5%	+$16.1K	0.02%	248
2022 Q4	$312K	Buy	11,096 +1,756	+19%	+$49.5K	0.03%	225
2022 Q3	$264K	Sell	9,340 -4,333	-32%	-$116K	0.02%	254
2022 Q2	$303K	Buy	13,673 +4,750	+53%	+$107K	0.03%	229
2022 Q1	$260K	Buy	+8,923	New	+$273K	0.01%	246

Other funds holding AGIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

E Fund Management's AGIO Position: Q2 2026 in Review

E Fund Management reduced its Agios Pharmaceuticals (AGIO) stake by 39% in Q2 2026, selling an estimated $154K and leaving 7,837 shares worth $291K. The position accounts for 0.01% of the portfolio, ranked #387.

E Fund Management first reported a position in AGIO in Q1 2022 and has held it in 12 quarters since. The position peaked at $437K in Q1 2026. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

E Fund Management held 7,837 shares of Agios Pharmaceuticals worth $291K as of Q2 2026.
E Fund Management sold 5,078 Agios Pharmaceuticals shares in Q2 2026, an estimated $154K.
Agios Pharmaceuticals made up 0.01% of E Fund Management's portfolio in Q2 2026, its #387 holding.
E Fund Management first reported a position in Agios Pharmaceuticals in Q1 2022 and has held it in 12 quarters since.
E Fund Management's Agios Pharmaceuticals position peaked at $437K in Q1 2026.
238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.